Articles

O.6 Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation – a multicenter prospective study

BJH - volume 11, issue Abstract Book BHS, february 2020

S. Servais MD, PhD, prof. F. Baron , C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, PhD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD

Read more

01 A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stromal cells after myeloablative or non-myeloablative conditioning in patients with haematological malignancies

BJH - volume 10, issue Abstract Book BHS, february 2019

A. De Becker MD, R. Schots MD, PhD, T. Kerre MD, PhD, D. Mazure MD, J. Maertens MD, PhD, E. Baudoux , C. Lechanteur , Y. Beguin MD, PhD

Read more

Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

BJH - volume 7, issue 6, december 2016

S. Servais MD, PhD, C. Grégoire MD, prof. F. Baron , E. Willems MD, PhD, A. Briquet PhD, E. Baudoux MD, O. Delloye PhD, O. Giet PhD, C. Lechanteur PhD, Y. Beguin MD, PhD

Summary

Steroid-refractory acute graft-versus-host disease is a severe complication after allogeneic stem cell transplantation. So far, its treatment remains very challenging since the current therapies do not offer significant benefits. Among the most recent approaches, multipotent mesenchymal stromal cell-based therapy has attracted great interest over the past decade. Here, we briefly reviewed the current knowledges about the immunomodulatory properties of multipotent mesenchymal stromal cells as well as results of preclinical and clinical studies having assessed their efficacy to modulate steroid-refractory acute graft-versus-host disease.

(BELG J HEMATOL 2016;7(6):229–35)

Read more

O.1 Infusion of mesenchymal stem cells (MSC) as treatment for steroid refractory acute graft-versus-host study (aGVHD): a multicenter prospective phase II study of the BHS

BJH - volume 7, issue Abstract Book BHS, january 2016

S. Servais MD, PhD, D. Selleslag MD, J. Maertens MD, PhD, L. Lechanteur , E. Baudoux MD, P. Zachée MD, PhD, H. Schouten , L. Noens MD, PhD, P. Lewalle MD, PhD, W. Schroyens MD, PhD, A. Ory , Y. Beguin MD, PhD

Read more

P3.03 Study of immune recovery in a randomized phase II trial of sequential double autologous transplantation with unmanipulated or AC133+ PBSC in patients with multiple myeloma

BJH - volume 6, issue Abstract Book BHS, january 2015

M. Hannon , S. Servais MD, PhD, R. Schots MD, PhD, E. Castermans , L. Seidel , A. Gothot MD, PhD, E. Baudoux MD, O. Giet PhD, N. Wanten , E. Willems MD, PhD, C. Daulne , I. Van Riet PhD, Y. Beguin MD, PhD, prof. F. Baron

Read more

O.6 Infusion of CliniMACS® (Miltenyi Biotec) enriched regulatory T-cells delays experimental xenogeneic graft-versus-host disease

BJH - 2013, issue BHS Abstractbook, january 2013

M. Hannon , C. Lechanteur PhD, J. Somja MD, PhD, S. Lucas , L. Belle , F. Bruck , E. Baudoux MD, Y. Beguin MD, PhD, S. Humblet-Baron , prof. F. Baron

Read more